Spring Bank Pharmaceuticals Announces Second Quarter 2016

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Spring Bank Pharmaceuticals Announces Second Quarter 2016 Financial Results and Recent Highlights

HOPKINTON, Mass., Aug. 01, 2016 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH ), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, cancer, and inflammatory diseases, today announced second quarter 2016 financial results and provided an update on recent corporate and clinical developments.

“We made good progress in the second quarter, achieving two major milestones for our company with the completion of our initial public offering and the dosing of the first patient in our ACHIEVE Phase 2a clinical trial of our lead compound, SB 9200, in Hepatitis B,” said Martin Driscoll, President and Chief Executive Officer of Spring Bank. “Chronic Hepatitis B remains a major global health challenge in need of a functional cure, and we believe SB 9200 has the potential to significantly improve the lives of patients living with this and other serious and chronic viral diseases. With a strengthened balance sheet from our IPO, we look forward to executing on the ACHIEVE Phase 2a trial and reporting topline data in the first half of next year.”

Second Quarter 2016 Research & Development Highlights

  • Dosed first patient in ACHIEVE global Phase 2a clinical trial of SB 9200 in HBV. The Phase 2a portion is a placebo-controlled, sequential-cohort, double-blind trial to evaluate increasing doses of SB 9200 (25mg, 50mg, 100mg and 200mg) as monotherapy for 12 weeks followed by tenofovir disoproxil fumarate (marketed by Gilead Sciences, Inc. as Viread®) 300 mg for an additional 12 weeks.
  • Presented preclinical data at the 29 th International Conference on Antiviral Research (ICAR). The data demonstrated that SB 9200 showed compelling antiviral activity in the woodchuck model of HBV and in RSV-infected mice consistent with the immunomodulatory mechanism of action of SB 9200.
  • Presented preclinical data at the 2016 European Association for the Study of the Liver (EASL) Annual Meeting. SB 9200 followed by entecavir resulted in significant declines in viral DNA, RNA and surface antigens in the woodchuck model of HBV. Additionally, SB 9200 inhibited the replication of HCV genotypes 1-6, including variants resistant to current direct-acting antivirals in patients who were treatment-naïve, responders or treatment-failures.
  • Continued to advance the pre-clinical development of SB 9200 for additional therapeutics uses. These include the fixed-dose combination of SB 9200 with the nucleoside/tide analogues for HBV and the formulation of SB 9200 for the intranasal route of administration in certain viral respiratory diseases.
  • Advanced the pre-clinical development of the Company's new small molecule nucleic acid hybrid compounds that activate the STING (STimulator of INterferon Genes) pathway in immuno-oncology and filed patent applications related to these novel, proprietary compounds. Recent published scientific literature indicates that STING can detect the presence of tumor cells and the activation of STING can result in induction of cellular Interferon production and promote an aggressive and strong anti-tumor response.                   

Second Quarter 2016 and Recent Corporate Developments

  • Completed an initial public offering and attained listing on the NASDAQ Capital Market. The Company sold 944,900 shares at an offering price of $12 per SBPH share, resulting in gross proceeds of $11.3 million. Additionally, the Company received $5.3 million from warrants exercised in connection with the IPO.
  • Appointed Dr. Todd Brady to the Board of Directors. Dr. Brady currently serves as Chief Executive Officer, President and Director of Aldeyra Therapeutics (Nasdaq: ALDX ), a developer of drugs for the treatment of inflammation and inborn errors of metabolism.  
  • Added to the Russell Microcap Index, effective June 27, 2016. As a result, SBPH shares were automatically included in the appropriate growth and value style index. Inclusion in the index remains in place for one year.

Second Quarter 2016 Financial Results

Net loss for the quarter ended June 30, 2016 was $(4.3) million, or $(0.62) per basic and diluted share, as compared to a net loss of $(2.3) million, or $(0.39) per basic and diluted share, for the same period in 2015.

Research and development expenses for the quarter ended June 30, 2016 were $2.9 million as compared to $1.5 million for the same period in 2015. The increase in R&D expenses was due to increased spending on clinical trial-related activities for the Company’s ongoing Phase 2a clinical trial of SB 9200.

General and administrative expenses for the quarter ended June 30, 2016 were $1.5 million as compared to $1.1 million for the same period in 2015. The increase in general and administrative expenses was due to additional salaries, benefits and stock-based compensation associated with higher headcount.

The weighted-average number of shares outstanding used to calculate basic and diluted loss per share was 6,923,941 in the second quarter of 2016 compared to 5,796,095 in the second quarter of 2015.

As of June 30, 2016, Spring Bank had $19.6 million of cash, cash equivalents and marketable securities.

About Spring Bank Pharmaceuticals

Spring Bank Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using its proprietary small molecule nucleic acid hybrid, or SMNH, chemistry platform. The company is developing its most advanced SMNH product candidate, SB 9200, for the treatment of viral diseases, including hepatitis B virus.

Forward-Looking Statements

Any statements in this press release about Spring Bank’s future expectations, plans and prospects, including statements about Spring Bank’s financial prospects, future operations and sufficiency of funds for future operations, clinical development of Spring Bank’s product candidates, expectations regarding future clinical trials and future expectations and plans and prospects for Spring Bank and other statements containing the words "believes," "anticipates," "estimates," "expects," "intends," "plans," "predicts," "projects," "targets," "may," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995.  Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including whether Spring Bank’s cash resources will be sufficient to fund its continuing operations for the periods anticipated; whether results obtained in clinical trials will be indicative of results obtained in future clinical trials; whether Spring Bank’s product candidates will advance through the clinical trial process on a timely basis; whether the results of such trials will warrant submission for approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; whether Spring Bank’s product candidates will receive approval from regulatory agencies on a timely basis or at all; whether, if product candidates obtain approval, they will be successfully distributed and marketed; and other factors discussed in the "Risk Factors" section of Spring Bank’s quarterly report on Form 10-Q for the quarter ended June 30, 2016, which is on file with the SEC,  and in other filings Spring Bank makes with the SEC from time to time. In addition, the forward-looking statements included in this press release represent Spring Bank’s views as of the date hereof. Spring Bank anticipates that subsequent events and developments will cause Spring Bank’s views to change. However, while Spring Bank may elect to update these forward-looking statements at some point in the future, Spring Bank specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Spring Bank’s views as of any date subsequent to the date hereof.

   
Spring Bank Pharmaceuticals, Inc.  
Consolidated Statements of Operations and Comprehensive Loss  
(unaudited)  
(in thousands, except share and per share data)  
   
    For the Three Months Ended June 30,   For the Six Months Ended June 30,  
      2016       2015       2016       2015    
Grant revenue   $ 72     $ 331     $ 352     $ 581    
Operating expenses:                  
Research and development     2,936       1,545       8,525       2,678    
General and administrative     1,458       1,054       2,684       2,129    
Total operating expenses     4,394       2,599       11,209       4,807    
Loss from operations     (4,322 )     (2,268 )     (10,857 )     (4,226 )  
Other income (expense):                  
Interest income     21       5       38       5    
Net loss     (4,301 )     (2,263 )     (10,819 )     (4,221 )  
Unrealized gain (loss) on marketable securities     4       (5 )     21       (5 )  
Comprehensive loss   $ (4,297 )   $ (2,268 )   $ (10,798 )   $ (4,226 )  
Net loss per common share – basic and diluted   $ (0.62 )   $ (0.39 )   $ (1.69 )   $ (0.76 )  
Weighted-average number of shares outstanding – basic and diluted     6,923,941       5,796,095       6,400,538       5,567,577    
                   
Spring Bank Pharmaceuticals, Inc.  
Consolidated Balance Sheets  
(in thousands, except share and per share data)  
   
    June 30,     December 31,  
      2016       2015    
ASSETS   (unaudited)      
Current assets:          
Cash and cash equivalents   $ 11,326     $ 4,347    
Marketable securities     8,289       5,335    
Prepaid expenses and other current assets     1,039       313    
Total current assets     20,654       9,995    
Marketable securities     —       3,189    
Property and equipment, net     523       427    
Other assets     —       966    
Total   $ 21,177     $ 14,577    
LIABILITIES AND STOCKHOLDERS’ EQUITY          
Current liabilities:          
Accounts payable   $ 2,858     $ 2,183    
Accrued expenses and other current liabilities     1,087       1,369    
Total liabilities     3,945       3,552    
Commitments (Note 7)          
Stockholders’ equity:          
Convertible preferred stock, $0.0001 par value—authorized, no shares and 5,000,000   shares at June 30, 2016 and December 31, 2015, respectively; no shares and 1,000,000   shares issued and outstanding at June 30, 2016 and December 31, 2015, respectively     —       —    
Preferred stock, $0.0001 par value—authorized, 10,000,000 and no shares at June 30,   2016 and December 31, 2015, respectively; 1,000,000 shares issued and no shares   outstanding at June 30, 2016; no shares issued and outstanding at December 31, 2015     —       —    
Common stock, $0.0001 par value—authorized, 200,000,000  and 50,000,000 shares at   June 30, 2016 and December 31, 2015, respectively; 7,757,734 and 5,796,091 shares   issued and outstanding at June 30, 2016 and December 31, 2015,   respectively     1       1    
Additional paid-in capital     62,216       45,211    
Accumulated deficit     (44,988 )     (34,169 )  
Other comprehensive income (loss)     3       (18 )  
Total stockholders’ equity     17,232       11,025    
Total   $ 21,177     $ 14,577    
         

Contacts: Jon Freve Chief Financial Officer (508) 473-5993 jfreve@springbankpharm.com Maeve Conneighton Argot Partners (212) 600-1902 maeve@argotpartners.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 495

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 0

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
KINGRVER Boosts RV Comfort with New Water Heater Lineup

Updated Category News Views 269

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 287

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 399

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 416

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 349

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 176

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 119

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Bloomberg, HKEX Expand Offshore RMB Bond Indices

Updated Category News Views 0

A Move to Elevate Dim Sum Bonds If you're wondering what's cooking in the bond market arena, Bloomberg and HKEX just turned up the heat with a new family of RMB bond indices. These aren't just any run-of-the-mill indices; they're targeting the offshore RMB market, affectionately called the Dim Sum bond market. For those of us grizzled vets in the trading world, this is...

Continue Reading

Top 5 Most Recently Viewed Articles

European Frozen Food Market Set for Major Growth, Companies Thrive

Updated Category News Views 277

European Frozen Food Market Set for Major Growth The frozen food market across Europe is poised for remarkable growth in the coming years, with an estimated increase of USD 62.5 billion from 2025 to 2029. With a projected compound annual growth rate (CAGR) of 7.6%, this sector is becoming increasingly attractive to investors and consumers alike. The desire for convenient...

Continue Reading
Mag Mile Capital's $10.25 Million Equity Venture in Chicago

Updated Category News Views 261

Mag Mile Capital Secures Significant Equity for Urban Transformation Mag Mile Capital, Inc. (OTCQB: MMCP) has achieved a significant milestone by securing $10.25 million in joint venture equity aimed at an innovative office-to-multifamily conversion project in Chicago. This project, situated at 111 W. Illinois, aims to repurpose a prominent office space in the vibrant...

Continue Reading
Nourishing Dogs and Communities: The Launch of Purposeful Pup Treats

Updated Category News Views 243

Purposeful Pup Treats Unveils New Launch for Furry Friends Purposeful Pup Treats, a brand passionate about the welfare of pets, has proudly launched a new range of all-natural, single-ingredient dog snacks. These treats are created with high-quality European ingredients and designed not just for the health of dogs, but also to uplift and strengthen communities. Embracing...

Continue Reading
Collaboration of Linux Foundation and ATIS to Transform Telecom

Updated Category News Views 151

Strategic Partnership for Innovative Network Solutions The Linux Foundation and the Alliance for Telecommunications Industry Solutions (ATIS) have joined forces to create a transformative impact on next-generation network architectures. This collaboration paves the way for advancements in open source and open RAN technologies, which are becoming increasingly important in...

Continue Reading
Vallourec Expands Operations with Significant Contracts

Updated Category News Views 245

Vallourec's Strategic Contracts in Iraq Vallourec, a global leader in premium seamless tubular solutions, has recently cemented two significant contracts for the supply of Oil Country Tubular Goods (OCTG). These contracts, established with major players CNOOC and PetroChina, reflect Vallourec's strength and expertise in supporting drilling operations in challenging...

Continue Reading